PUS10

Across TCGA pan-cancer cohorts, PUS10 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PUS10’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PUS10 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PUS10 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where PUS10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PUS10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.373	<.001	9	view →
LSCC	Male	All	+0.165	<.001	6	view →
PDAC	All	II,III,IV	−0.226	.002	5	view →
LUAD	Female	All	+0.149	.004	5	view →
HNSC	All	All	−0.263	.010	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PUS10–CCRCC

Open the CCRCC breakdown →